Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Embecta Corp. (JX7.F)

Compare
10.60
-0.20
(-1.85%)
At close: April 15 at 8:26:20 PM GMT+2
Loading Chart for JX7.F
  • Previous Close 10.80
  • Open 10.30
  • Bid --
  • Ask --
  • Day's Range 10.30 - 10.60
  • 52 Week Range 9.25 - 19.90
  • Volume 5
  • Avg. Volume 28
  • Market Cap (intraday) 616.225M
  • Beta (5Y Monthly) 1.18
  • PE Ratio (TTM) 12.18
  • EPS (TTM) 0.87
  • Earnings Date May 7, 2025 - May 12, 2025
  • Forward Dividend & Yield 0.55 (5.12%)
  • Ex-Dividend Date Feb 28, 2025
  • 1y Target Est --

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

www.embecta.com

2,100

Full Time Employees

September 30

Fiscal Year Ends

Recent News: JX7.F

View More

Performance Overview: JX7.F

Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

JX7.F
40.76%
S&P 500 (^GSPC)
8.25%

1-Year Return

JX7.F
16.57%
S&P 500 (^GSPC)
6.61%

3-Year Return

JX7.F
61.68%
S&P 500 (^GSPC)
22.86%

5-Year Return

JX7.F
61.68%
S&P 500 (^GSPC)
93.89%

Compare To: JX7.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: JX7.F

View More

Valuation Measures

Annual
As of 4/14/2025
  • Market Cap

    609.97M

  • Enterprise Value

    1.82B

  • Trailing P/E

    12.37

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.65

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    1.86

  • Enterprise Value/EBITDA

    11.40

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.25%

  • Return on Assets (ttm)

    3.13%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.11B

  • Net Income Avi to Common (ttm)

    58.2M

  • Diluted EPS (ttm)

    0.87

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    210M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -37.41M

Research Analysis: JX7.F

View More

Company Insights: JX7.F

Research Reports: JX7.F

View More

People Also Watch